Dr. Pui on Utilizing CAR T-Cell Therapy in Pediatric ALL

Video

Ching-Hon Pui, MD, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia.

Ching-Hon Pui, MD, chair, Oncology Department, St. Jude Children's Research Hospital, discusses the use of CAR T-cell therapy in patients with relapsed/refractory acute lymphocytic leukemia (ALL).

CAR T-cell therapy is currently used in pediatric patients with relapsed/refractory ALL. Increasingly, it is used to treat patients with central nervous system relapsed or testicular relapse, says Pui.

In the past, pediatric patients with ALL required radiation to be cured; however, now CAR T-cell therapy can cure those patients without the use of radiation. Pui believes that in the near future, CAR T-cell therapy will be used to treat patients with high-risk ALL and avoid intensive chemotherapy altogether, improving the patient's quality of life as well as the cure rate.

Related Videos
Vivien Sheehan, MD, PhD, an associate professor of pediatrics at Emory University
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
© 2024 MJH Life Sciences

All rights reserved.